Cover Image

Evaluation of the acute effects of single‐dose TPN171 on semen quality in healthy Chinese male volunteers

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Yuzhuo Yang, Zhe Zhang, Lei Li, Zhicheng Jiang, Jiaxiang Juan, Huaqing Duan, Zhen Wang, Hui Jiang
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	British Journal of Clinical Pharmacology
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pharmacokinetics, safety, tolerability and fluorescence imaging of nizaracianine triflutate administered in three divided doses to healthy volunteers
by: Lisanne K. A. Neijenhuis, et al.
Published: (2026)

Effects on cerebral blood flow after single doses of the β2 agonist, clenbuterol, in healthy volunteers and patients with mild cognitive impairment or Parkinson's disease
by: Thomas Lodeweyckx, et al.
Published: (2024)

Why do healthy volunteers participate in clinical trials?
by: Thijs van Iersel, et al.
Published: (2026)

Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies
by: Yuji Kumagai, et al.
Published: (2025)

Pharmacokinetic parameters of bictegravir in breastmilk of healthy, lactating volunteers without HIV after a single dose of 50 mg (co‐formulated with emtricitabine 200 mg and tenofovir alafenamide 25 mg)
by: L. Van Der Wekken‐Pas, et al.
Published: (2025)

Epidural methadone and morphine pharmacokinetics and clinical effects in healthy volunteers: A randomized, crossover‐design trial
by: Alexander Hincker, et al.
Published: (2024)

An open‐label, single‐arm, dose‐escalating concentration–QT study to investigate the cardiac effects and safety of paroxetine in healthy adults
by: Sven C. van Dijkman, et al.
Published: (2026)

Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase‐1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose study
by: Yuhao Wang, et al.
Published: (2025)

Repeated intradermal lipopolysaccharide challenge responses in healthy volunteers: Implications for clinical pharmacology studies
by: Alexandra A. J. Sillé, et al.
Published: (2026)

Model‐based precision dosing and remedial dosing recommendations for delayed or missed doses of isoniazid in Chinese patients with tuberculosis
by: Jin‐Meng Li, et al.
Published: (2024)

Population pharmacokinetic/target engagement modelling of tozorakimab in healthy volunteers and patients with chronic obstructive pulmonary disease
by: Muhammad Waqas Sadiq, et al.
Published: (2024)

Establishing reference ranges for circulating biomarkers of drug‐induced liver injury in healthy human volunteers 1
by: Andrea L. Jorgensen, et al.
Published: (2024)

Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants
by: Jean‐Yves Gillon, et al.
Published: (2025)

A phase I study to evaluate the safety, tolerance and pharmacokinetics of anti‐Shiga toxin hyperimmune equine F (ab′)2 fragments in healthy volunteers
by: Yanina Hiriart, et al.
Published: (2024)

A randomized phase I study of the safety and pharmacokinetics of BI 1291583 in healthy Japanese male subjects
by: Yusuke Tadayasu, et al.
Published: (2024)

Hypnotic doses of fazamorexant induced less impairment on balance and cognition than zolpidem in healthy younger and elderly individuals
by: Chen Xia, et al.
Published: (2026)

Tolerability and pharmacokinetics of leritrelvir in Chinese participants with severe renal impairment and healthy matched control subjects
by: Zi‐yi Zhou, et al.
Published: (2026)

Letter to the Editor of the British Journal of Clinical Pharmacology Re: van Iersel et al. (2026)—Why do healthy volunteers participate in clinical trials? doi: https://doi.org/10.1002/bcp.70499
by: Kasra Shakeri‐Nejad, et al.
Published: (2026)

Single‐dose pharmacokinetics and safety of ACC017, a novel HIV integrase inhibitor, in healthy adult participants: A first‐in‐human study
by: C. Hu, et al.
Published: (2025)

A phase 1, randomized, crossover trial to assess the effect of itraconazole on the pharmacokinetics of dordaviprone in healthy adults
by: Shamia L. Faison, et al.
Published: (2025)

Current evidence and insights on single vs. double dose of basiliximab in adult solid organ transplant recipients: A systematic review
by: Alessio Provenzani, et al.
Published: (2025)

Interindividual variability in olanzapine steady‐state concentrations in Chinese: exploring single nucleotide polymorphisms of metabolic enzymes
by: Zhou Wan, et al.
Published: (2025)

Safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of HRS‐1893, a cardiac myosin inhibitor, in healthy subjects
by: Kexu Yang, et al.
Published: (2026)

Temporal effects of errors in estimating kidney function after critical illness on drug dosing categories
by: Ryusei Mikami, et al.
Published: (2025)

Model‐informed vancomycin precision dosing by population pharmacokinetics combined with machine learning algorithms
by: Lei Shi, et al.
Published: (2026)

Pharmacodynamics, pharmacokinetics and CYP3A4 interaction potential of the selective P2X3 receptor antagonist filapixant: A randomized multiple ascending‐dose study in healthy young men
by: Christian Friedrich, et al.
Published: (2024)

Mechanism‐informed machine learning for individualized tacrolimus dose adjustment in the early post‐kidney transplant period
by: Hui Yu, et al.
Published: (2026)

An experimental medicine protocol for exploring the haemodynamic effects of dual agonism at the glucagon‐like peptide‐1 and glucagon receptor in healthy subjects
by: James Goodman, et al.
Published: (2025)

Model‐informed dose selection for an investigational human epidermal growth factor receptor 2 antibody–drug conjugate FS‐1502 in patients with human epidermal growth factor receptor 2‐expressing advanced malignant solid tumours
by: Yi Sun, et al.
Published: (2024)

Effect of fluconazole on the pharmacokinetics of ainuovirine in healthy adult subjects
Published: (2024)

Comparing the efficacy of efgartigimod and intravenous immunoglobulin on AQP4‐IgG‐positive neuromyelitis optica spectrum disorder during acute attacks
by: Jia Liu, et al.
Published: (2025)

Population pharmacokinetics of TBAJ‐587 and its main metabolites—Evaluation of different loading dose strategies and early dose selection
by: Albin A. M. Leding, et al.
Published: (2025)

The feasibility of pharmacokinetic‐based dosing of hydroxyurea for children with sickle cell anaemia in Uganda: Baseline results of the alternative dosing and prevention of transfusions trial
by: Alexandra Power‐Hays, et al.
Published: (2025)

Practical dose ranges supporting target vancomycin exposure with AUC‐guided dosing in overweight and obese patients: A multicentre retrospective study
by: Aiju Endo, et al.
Published: (2026)

Methotrexate toxicity and glucarpidase: A call for dose optimization
by: Arjen Koppen, et al.
Published: (2025)

Determination of the optimal obesity‐adjusted dosing weight for enoxaparin
by: Gregory W. Roberts, et al.
Published: (2024)

Evaluation of the effect of CYP2D6 and OCT1 polymorphisms on the pharmacokinetics of tramadol: Implications for clinical safety and dose rationale in paediatric chronic pain
by: Paul Healy, et al.
Published: (2024)

AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma
by: Anna Lundahl, et al.
Published: (2025)

Characterizing local and systemic exposure to clobetasol propionate in healthy subjects and patients with atopic dermatitis
by: Janna K. Duong, et al.
Published: (2025)

Concentration‐QTc analysis of soticlestat in healthy adults: An alternative to a thorough QT study
by: Wei Yin, et al.
Published: (2024)